期刊
BLOOD
卷 121, 期 22, 页码 4439-4442出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2013-03-490003
关键词
-
类别
资金
- National Institute for Health Research [NF-SI-0611-10275] Funding Source: researchfish
- Grants-in-Aid for Scientific Research [23591379] Funding Source: KAKEN
As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据